Neither age, sex, GH, IGF-1 (nmol/L) and IGF-1/ULN levels, tumor size (macroadenoma vs. microadenoma) and first treatment modality (surgery vs. 1st generation SSAs) predicted control at long-term follow-up. This evidence concerns the gene GH1 and neoplasm.